REG - Dechra Pharmaceutcls - Appointment of John Shipsey as Non-Executive

Dechra PharmaceuticalsAnnouncement

17/05/2022 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220517:nRSQ7891La&default-theme=true

RNS Number : 7891L  Dechra Pharmaceuticals PLC  17 May 2022

17 May 2022

 

Dechra(®) Pharmaceuticals PLC

(Dechra, the Company or the Group)

 

Appointment of John Shipsey as Non-Executive Director

 

 

Dechra is pleased to announce that, with effect from 1 June 2022, John Shipsey
will be appointed as a Non-Executive Director of the Company.  John will be a
member of the Group's Audit, Remuneration and Nomination Committees with the
intention that he will be appointed as Chair of the Audit Committee upon
Julian Heslop's retirement as Audit Committee Chairman on 1 September 2022.

 

John has valuable experience leading innovative, high growth companies and
brings a wealth of financial and commercial experience to the business.  In
addition, his recent tenure as Chief Financial Officer at FTSE100 Smiths Group
PLC (January 2018 to April 2022) will be a highly relevant asset to the Board
and Dechra.  Prior to this he was Chief Financial Officer for Dyson, the
diversified global technology company where he was part of the team that led
its international growth, particularly in Asia.  His previous experience
includes a number of senior finance and strategy roles over 13 years at Diageo
plc, including Finance Director for its Iberia region and Chief Financial
Officer of Schieffelin & Somerset, a US joint venture between Diageo and
LVMH.

 

John is a Chartered Accountant and has an MBA from INSEAD.

 

There are no other disclosures to be made in respect of John Shipsey, pursuant
to Listing Rule 9.6.13R.

 

 

 Enquiries to:
 Dechra Pharmaceuticals PLC
 Ian Page, Chief Executive Officer
 Office:  +44 (0) 1606 814 730
 e-mail: corporate.enquiries@dechra.com (mailto:corporate.enquiries@dechra.com)

 TooleyStreet Communications Ltd
 Fiona Tooley, Director

 Mobile: +44 (0) 7785 703 523

 e-mail: fiona@tooleystreet.com (mailto:fiona@tooleystreet.com)

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products
business.  Our expertise is in the development, manufacture and sales and
marketing of high quality products exclusively for veterinarians worldwide.
Dechra's business is unique as the majority of its products are used to treat
medical conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.

 

For more information please visit: www.dechra.com (http://www.dechra.com)

Stock Code: Full Listing (Pharmaceuticals): DPH

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABDLFFLELBBBL